Fremont, California, USA — September 3, 2026
Cytek Biosciences, Inc. announced that it will showcase its spectral flow cytometry and cell analysis solutions at two major clinical cytometry meetings, the European Society for Clinical Cell Analysis (ESCCA) 2026 Conference and the 41st Annual International Clinical Cytometry Meeting & Course (ICCS 2026). The company’s participation is focused on demonstrating how its Full Spectrum Profiling (FSP) technology can support increasingly complex cell analysis workflows across clinical research and translational applications. Cytek said its spectral technology captures the full spectrum of fluorescent signals, allowing laboratories to work with more complex panels while supporting streamlined workflows and deeper analysis of individual samples. The company highlighted that its FSP systems have been cited in more than 4,200 peer-reviewed publications, reflecting their use across areas including cell biology, immunology, oncology and clinical research.
Cytek Showcases Spectral Cytometry at ESCCA 2026
At ESCCA 2026, taking place September 9–12 in Salzburg, Austria, Cytek will showcase its broad portfolio of cell analysis solutions at Booth PL2. The company’s presence will focus on the growing role of spectral flow cytometry in clinical and translational research, particularly as laboratories seek greater analytical capabilities, workflow efficiency and data quality. Cytek will also host an Industrial Partner Presentation on September 11 titled “Do We Really Need 40 Colors? Rethinking Spectral Cytometry for Routine Diagnostics and MRD Monitoring.” The session will examine the potential role of spectral cytometry in routine laboratory workflows and minimal residual disease (MRD) monitoring, with perspectives from clinical hematology. The event is expected to bring together clinicians, researchers and cytometry specialists working across hematology, immunology, oncology and cell biology.
Cytek Expands Clinical Research Applications
The company is also preparing for ICCS 2026, scheduled for October 2–6 in Miami, Florida. Cytek will exhibit at Booths 100/101 and host a Corporate Workshop addressing developments in clinical flow cytometry. Through its participation in both events, Cytek aims to highlight how spectral technology is expanding beyond conventional flow cytometry approaches and supporting increasingly sophisticated cell analysis applications. The company said laboratories are increasingly looking for technologies that can combine multiplexing, sensitivity, analytical depth and workflow efficiency while supporting greater standardization. Cytek’s FSP approach is designed to use information contained across the complete fluorescent spectrum, enabling laboratories to analyze complex multicolor panels and generate additional information from limited biological samples.
Advertisement
Cytek Advances Full Spectrum Profiling Technology
Cytek Biosciences continues to build its cell analysis portfolio around its patented Full Spectrum Profiling technology, with solutions spanning spectral flow cytometry instruments, reagents, software and related services. Its portfolio includes the Cytek Aurora, Northern Lights, Aurora CS and Aurora Evo systems, alongside additional cell analysis and imaging technologies under the Muse, Amnis and Guava brands. Cytek said its objective is to help laboratories generate more actionable cellular insights while simplifying workflows and making better use of laboratory resources. The company’s participation at ESCCA and ICCS 2026 reflects its focus on supporting the continued adoption of spectral flow cytometry across clinical research and translational environments, including emerging applications such as MRD research. Cytek also plans to facilitate discussions with clinical experts through presentations and KOL meetings at both conferences, highlighting the evolving role of spectral cell analysis in modern laboratory research.
Source: Cytek Biosciences press relese
